BIOGEN INC.
For the period ended Jun 30, 2026. Filed Jul 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
ITEM 5. OTHER INFORMATION
TRADING ARRANGEMENTS
From time to time, our officers (as defined in Rule 16a-1(f)) and directors may enter into, amend or terminate Rule 10b5-1 ornon-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the second quarter of 2026, our officers and directors took the following actions with respect to trading arrangements:
| Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Name and Position | Action | Date | Rule10b5-1 | Non-Rule 10b5-1 | Total Shares to be Purchased or Sold | Expiration Date |
| Priya Singhal, M.D., EVP, Head of Development(1) | Adopt | 4/30/2026 | X | — | 20,400 | 10/29/2027 |
| Lloyd Minor, Director | Adopt | 5/4/2026 | X | — | 593 | 8/7/2026 |
(1) Dr. Singhal's Rule 10b5-1 trading arrangement provides for the sale of (i) up to 20,400 shares of our common stock and (ii) all of the shares of our common stock to be acquired under our Employee Stock Purchase Plan during the term of the 10b5-1 trading arrangement. The number of shares to be acquired under the plan is not determinable at this time as the purchase price for such shares will be determined at the end of the applicable purchase period under the plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.